Literature DB >> 23557915

Down-regulation of miR-223 contributes to the formation of Gottron's papules in dermatomyositis via the induction of PKCɛ.

Kuniko Inoue1, Masatoshi Jinnin, Keitaro Yamane, Takamitsu Makino, Ikko Kajihara, Katsunari Makino, Norithosi Honda, Wakana Nakayama, Satoshi Fukushima, Hironobu Ihn.   

Abstract

BACKGROUND: Dermatomyositis (DM) is characterized by skin manifestations accompanying and preceding muscle weakness. Gottron's papules, one of the skin manifestations, are of great diagnostic value because they are specific to DM. However, the pathogenesis of Gottron's papules remains unclear.
OBJECTIVES: We investigated the expression pattern of miRNAs in Gottron's papules of DM patients and evaluated the possibility that miRNAs play a role in its pathogenesis.
MATERIALS AND METHODS: miRNAs were extracted from skin tissues and sera of patients with DM, clinically amyopathic DM (CADM) and healthy controls. To identify pathogenic miRNAs, we performed miRNA PCR array analysis. The results were confirmed by in situ hybridization, immunohistochemistry, immunoblotting and transient transfection of siRNAs or miRNA inhibitors.
RESULTS: PCR array analysis using tissue miRNAs demonstrated the miR-223 level was markedly decreased in Gottron's papules of DM and CADM in vivo, but not in psoriasis skin. The protein expression of PKCɛ, a predicted target of miR-223, was increased in DM/CADM skin. The transfection of a specific inhibitor of miR-223 in keratinocytes led to up-regulation of the PKCɛ protein, and resulted in increased cell proliferation. On the other hand, cell numbers were significantly decreased when cells were transfected with siRNA for PKCɛ. The serum miR-223 concentration was decreased in DM/PM patients, particularly in CADM patients, compared with healthy controls.
CONCLUSIONS: A decreased miR-223 expression and the subsequently increased PKCɛ levels may therefore play a key role in the pathogenesis of Gottron's papules.

Entities:  

Keywords:  autoimmune disease; collagen disease; keratinocyte; microRNA; serum

Mesh:

Substances:

Year:  2013        PMID: 23557915     DOI: 10.1684/ejd.2013.1959

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  7 in total

Review 1.  Epigenetics in Non-tumor Immune-Mediated Skin Diseases.

Authors:  M C Ovejero-Benito; E Daudén; Alejandra Reolid; E Muñoz-Aceituno; F Abad-Santos
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

2.  [Advances in epigenetic markers of dermatomyositis/polymyositis].

Authors:  Y Y Yang; X X Zuo; H L Zhu; S J Liu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-04-18

3.  Study of microRNAs (miRNAs) that are predicted to target the autoantigens Ro/SSA and La/SSB in primary Sjögren's Syndrome.

Authors:  V C Gourzi; E K Kapsogeorgou; N C Kyriakidis; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2015-07-21       Impact factor: 4.330

4.  Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis.

Authors:  Takuya Hirai; Keigo Ikeda; Hiroshi Tsushima; Maki Fujishiro; Kunihiro Hayakawa; Yuko Yoshida; Shinji Morimoto; Ken Yamaji; Yoshinari Takasaki; Kenji Takamori; Naoto Tamura; Iwao Sekigawa
Journal:  Inflamm Regen       Date:  2018-01-08

5.  MicroRNA and mRNA profiling in the idiopathic inflammatory myopathies.

Authors:  Joanna E Parkes; Anastasia Thoma; Adam P Lightfoot; Philip J Day; Hector Chinoy; Janine A Lamb
Journal:  BMC Rheumatol       Date:  2020-06-10

6.  Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis.

Authors:  Lifang Ye; Yu Zuo; Hanbo Yang; Wenli Li; Qinglin Peng; Xin Lu; Guochun Wang; Xiaoming Shu
Journal:  J Immunol Res       Date:  2019-02-19       Impact factor: 4.818

Review 7.  Polishing the crystal ball: mining multi-omics data in dermatomyositis.

Authors:  Rochelle L Castillo; Alisa N Femia
Journal:  Ann Transl Med       Date:  2021-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.